AngioDynamics Down 5.8% with RSI at 9.16 as EPS Estimates Rise 24.1%
AngioDynamics shares have dropped 5.8% over the past four weeks, with its RSI plunging to 9.16 well below the 30 oversold threshold. Meanwhile, sell-side analysts have raised AngioDynamics’ consensus EPS estimate 24.1% in 30 days, earning it a Zacks Rank #2 Buy.
1. Recent Price Decline and Technical Oversold
AngioDynamics has declined 5.8% over the past four weeks as heavy selling pressure pushes its Relative Strength Index (RSI) down to 9.16, far below the 30 threshold that signals oversold conditions. This extreme RSI reading suggests a potential exhaustion of the downtrend and a technical setup for a price reversal.
2. Consensus EPS Revisions Surge
Over the last 30 days, the consensus EPS estimate for the current fiscal year has increased by 24.1%, reflecting growing confidence among analysts in AngioDynamics’ near-term earnings outlook. An upward trend in earnings estimate revisions often precedes stock price appreciation.
3. Zacks Rank #2 Highlights Buy Potential
AngioDynamics holds a Zacks Rank #2 (Buy), placing it in the top 20% of more than 4,000 stocks based on positive trends in earnings estimate revisions and EPS surprises. This ranking underscores the stock’s potential upside as estimate upgrades align with improved fundamentals.